CD28+PD-1+ Tc-cell enrichment may serve as a potential marker in HCC, and therapeutic strategies targeting different levels of CD28+PD-1+ Tc-cell enrichment could offer new directions for improving HCC treatment outcomes. This evidence concerns the gene CD28 and hepatocellular carcinoma.